Background: The aim of this review was to assess the quality of international treatment
guidelines for post-traumatic stress disorder (PTSD), and identify differences between …

As recovery is a multidimensional concept, some authors suggested that at least two areas
should be taken into account: clinical remission and social functioning. Functional outcome …

Abstract Using Richardson and Davidson's model and the sciences of pharmacokinetics and
clinical pharmacopsychology, this article reviewed the:(1) poor life expectancy associated …

Although some studies have suggested that relapse may be associated with antipsychotic
treatment resistance in schizophrenia, the number and quality of studies is limited. The …

Objective It is estimated that up to 75% of patients with severe mental illness (SMI) also have
substance use disorder (SUD). The aim of this systematic review was to explore the scope …

Background Antipsychotic doses for relapse prevention in patients with first-episode
schizophrenia that have the highest likelihood of success are unknown. We aimed to study …

Importance Schizophrenia is generally considered to be among the most severe psychiatric
disorders because of the excessive mortality associated with it. Research to find means to …

Aim Long acting injectable (LAI) antipsychotics are an alternative to oral antipsychotic (OAP)
treatment and may be beneficial for patients in the early stages of schizophrenia. This study …

Aim Long‐acting injectable antipsychotic drugs (LAIs) are often used as an alternative to
oral antipsychotics (OAPs) in individuals with psychosis who demonstrate poor medication …

Olanzapine is a second-generation atypical antipsychotic with proven efficacy for the
treatment of schizophrenia. Approved in 1996, olanzapine is one of the most studied …